TP53 and colorectal carcinoma: However, it is interesting to note that ~ 50% of CMS4 tumors display TP53 mutations and generally lack mutations in BRAF, and that loss of NCLX is statistically linked to TP53 mutant tumors and wild type BRAF CRC tumors.